Reducing Risk of Dementia Through Deprescribing

A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.

Inclusion Criteria for Participants: * Age 65 and older; * At least one office visit to their primary care physician within the previous 12 months; * Use of a target anticholinergic medication within the last two weeks OR medical record evidence of exposure to target anticholinergic medications at or above a cognitive risk threshold in the prior 12 months * Able to communicate in English; * Access to a telephone Exclusion Criteria for Participants: * Permanent resident of an extended care facility (nursing home) * Diagnosis of schizophrenia, bipolar disorder, or schizoaffective disorder defined by International Classification of Diseases (ICD) version 9/10 codes * Diagnosis of Alzheimer's Disease or Related Dementia as determined by (a), (b), or (c) below: 1. ICD-9/10 codes, or 2. Current use of a medication for Alzheimer's Disease or a Related Dementia, or 3. A pattern of responses to the Functional Activities Questionnaire (FAQ) that indicate dementia (i.e., ≥ 3 FAQ items are scored at "requires assistance," or if ≥ 1 FAQ item is scored at "dependent").